Wikipedia -WSS

Wikipedia

author：fashion 2025-09-29 01:08:21 - browse：4182

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Medicare drug price negotiation hearing pits pharma v Biden admin

WSS

Why failed clinical trials don’t always spell doom for a new drug

Ancient Greek ideas underpin modern concepts of pregnancy

What to know about Virgin Galactic's 1st mission taking paying customers to space

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Readout Newsletter: BridgeBio, Akero, and human embryo models

South Korea throws huge K

focus

Wikipedia

Wikipedia

Cancer drug shortages should be causing more outrage

Medicare drug price negotiation hearing pits pharma v Biden admin

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to use technology to prevent future drug shortages

Novavax promises a turnaround & Lilly roils the obesity market

Fetal cell organoids grown from amniotic fluid, study finds

Bright Health sells Medicare Advantage business to Molina

The best solution to the drug shortages problem

The cancer drug shortage isn’t new — and neither are the solutions

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

knowledge

First over

Change Healthcare: What is it, why does its cyberattack matter?

Why Talkspace is targeting Medicare, a tricky market

Naloxone nonprofit donates 200,000 doses after FDA approval

South Korea throws huge K

For AI in health care standards, federal regulators join with industry group

leisure time

hotspot

Wikipedia

focus